Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab for calcinosis lesions in juvenile dermatomyositis
IRCT20210808052107N1Phase 2Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of infliximab in juvenile dermatomyositis (JDM) and calcinosis, sponsored by Shahid Beheshti University of Medical Sciences. Started Apr 2022; status: completed.
02
Drugs
infliximab
03
Conditions
juvenile dermatomyositis (JDM)calcinosis
Beyond the preview
Go deeper on IRCT20210808052107N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210808052107N1.